1. Search Result
Search Result
Results for "

ECD

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

2

Peptides

13

Inhibitory Antibodies

12

Recombinant Proteins

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99380
    Zanidatamab
    1 Publications Verification

    ZW 25

    EGFR Cancer
    Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .
    Zanidatamab
  • HY-18377

    DR5 Activator

    TNF Receptor Apoptosis Cancer
    Bioymifi (DR5 Activator), a potent TRAIL receptor DR5 activator, binds to the extracellular domain (ECD) of DR5 with a Kd of 1.2 μM. Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis .
    Bioymifi
  • HY-RS17935

    Small Interfering RNA (siRNA) Others

    Ecd Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ecd gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ecd Mouse Pre-designed siRNA Set A
    Ecd Mouse Pre-designed siRNA Set A
  • HY-RS24405

    Small Interfering RNA (siRNA) Others

    Ecd Rat Pre-designed siRNA Set A contains three designed siRNAs for Ecd gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ecd Rat Pre-designed siRNA Set A
    Ecd Rat Pre-designed siRNA Set A
  • HY-RS04132

    Small Interfering RNA (siRNA) Others

    ECD Human Pre-designed siRNA Set A contains three designed siRNAs for ECD gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ECD Human Pre-designed siRNA Set A
    ECD Human Pre-designed siRNA Set A
  • HY-P990759

    CD22 Inflammation/Immunology
    Rezetamig is an anti-CD3E/CD22 monoclonal antibody .
    Rezetamig
  • HY-P991239

    EGFR Cancer
    NM-02 is an antibody targeting HER2 with an EC50 value of 1.2 nM. NM-02 binds to domains I and II of HER2-ECD, blocking HER2-related signaling pathways. NM-02 is promising for research of HER2-positive breast cancer .
    NM-02
  • HY-P99963

    HS636

    PD-1/PD-L1 Cancer
    Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .
    Sudubrilimab
  • HY-P991331

    CD73 Cancer
    BC-010 is a human monoclonal antibody (mAb) targeting NT5E/CD73. BC-010 can be used in the study of tumors.
    BC-010
  • HY-P990903

    CD3 Inflammation/Immunology
    HY-P990903 is an CD3E/CD33-targeting [H-γ1 _ L-κ-scFv heavy -κ]-dimer type bispecific antibody .
    Avitotamig
  • HY-P991332

    CD73 Cancer
    JAB-BX102 is a human monoclonal antibody (mAb) targeting NT5E/CD73. JAB-BX102 can be used in the study of cancers such as breast cancer, pancreatic cancer, and prostate cancer .
    JAB-BX102
  • HY-P991330

    CD73 Cancer
    BMS-986179 is a human monoclonal antibody (mAb) targeting NT5E/CD73. BMS-986179 inhibits CD73 enzymatic activity in tumor vasculature and tumor cells. BMS-986179 can be used in advanced solid tumors research .
    BMS-986179
  • HY-P990969

    CD3 Inflammation/Immunology
    HY-P990969 is an CD3E/CD4-targeting IgG1 λ1 type humanized antibody, the recommed isotype control is Human IgG1 lambda1, Isotype Control (HY-P99992) .
    Amtabafusp alfa
  • HY-P991028

    AZD0486; TNB-486

    CD3 Inflammation/Immunology
    HY-P991028 is an CD3D/CD3E/CD19-targeting (H-γ4_L-κ)_VH-G4(h-CH2-CH3) type bispecific antibody .
    Surovatamig
  • HY-P991443

    CD73 Cancer
    IPH5301 is a human IgG1 monoclonal antibody (mAb) targeting NT5E/CD73. IPH5301 has a functionally silent Fc domain, specifically inhibits soluble and membrane CD73 enzyme activity, and restores the proliferation of immune T cells. IPH5301 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    IPH5301
  • HY-P10495

    Transmembrane Glycoprotein Others Cancer
    GPR110 peptide agonist P12 is a peptide that acts as a GPR110 agonist. GPR110 peptide agonist P12 can significantly enhance the initial rate of GPR110 stimulated G protein GTPγS binding. GPR110 peptide agonist P12 mimics the action of natural ligands, causing the extracellular domain (ECD) of the GPR110 to dissociate from the seven transmembrane domains (7TM), exposing the β-strand-13/stalk region at the N-terminus of the 7TM domain, which acts as an agonist to activate G protein signaling. GPR110 peptide agonist P12 can be used in the study of developmental disorders and cancers related to GPR110 .
    GPR110 peptide agonist P12

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: